<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602339</url>
  </required_header>
  <id_info>
    <org_study_id>19773</org_study_id>
    <secondary_id>2018-000690-78</secondary_id>
    <nct_id>NCT03602339</nct_id>
  </id_info>
  <brief_title>Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose</brief_title>
  <acronym>LEADER75</acronym>
  <official_title>LowEr Administered Dose With highEr Relaxivity: Gadovist vs Dotarem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to gain knowledge about a new dose of a diagnostic drug that is
      used for contrast-enhanced Magnetic Resonance Imaging (MRI) of the human central nervous
      system (CNS). MRI can visualize the anatomy of the body and is used to detect medical
      conditions. Diagnostic drugs like gadobutrol and gadoterate contain an element called
      gadolinium that is applied to improve the analysability of MRI-images.

      The purpose of this study is to examine if contrast-enhanced MRI using a reduced dose of the
      gadolinium-based contrast agent gadobutrol delivers images of similar quality to those
      obtained when a full dose of the gadolinium-based contrast agent gadoterate is used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label, multi-center, comparative, cross-over trial in adult patients
      with known or highly suspected CNS pathology who were referred for imaging of the CNS.

      The primary objective of the study is to demonstrate the non-inferiority of gadobutrol (0.075
      mmol/ kg body weight) to gadoterate (0.1 mmol/ kg body weight).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">May 26, 2020</completion_date>
  <primary_completion_date type="Actual">March 13, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of lesion contrast enhancement</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Blinded readers will score up to 5 lesions using image sequences and a 4-point scale (1 - No = Lesion not enhanced; 2 - Moderate = Lesion weakly enhanced; 3 - Good = Lesion clearly enhanced; 4 - Excellent = Lesion clearly and brightly enhanced)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion border delineation</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Blinded readers will score the delineation of up to 5 lesions using image sequences and a 4-point scale (1 - None = No or unclear delineation; 2 - Moderate = Partial delineation; 3 - Good = Almost clear, but incomplete delineation; 4 - Excellent = Clear and complete delineation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion internal morphology</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Blinded readers will score the structure and internal morphology of up to 5 lesions using image sequences and a 3-point scale (1 - Poor = Poor visibility; 2 - Moderate = Partial visibility; 3 - Good = Sufficient visibility)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lesions</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Blinded reader will count the total number of lesions up to a maximum of 10 lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of benign or malignant disease</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Blinded readers will determine the benignity or malignancy of the pathology from MRI images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confidence in diagnosis</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Blinded readers will rate their confidence in diagnosis according to a 4-point scale (1 - Not confident; 2 - Somewhat confident; 3 - Confident; 4 - Very confident).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image quality</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Blinded Readers will assess the image quality of gadobutrol- and gadoterate-enhanced images (randomly assigned as left [L] and right [R] image positions) according to a 5-point scale (1- Image R is worse; 2 - Image R is slightly worse; 3- Image R is similar; 4 - Image R is slightly better; 5 - Image R is better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast enhancement</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Using an exploratory overall contrast enhancement estimation algorithm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>Arm 1_Suspected CNS-lesion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with suspected or confirmed CNS-lesions will undergo unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2_Confirmed CNS-lesion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) will undergo a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadoterate (Dotarem®/Clariscan™)</intervention_name>
    <description>Patients receive a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.</description>
    <arm_group_label>Arm 1_Suspected CNS-lesion</arm_group_label>
    <arm_group_label>Arm 2_Confirmed CNS-lesion</arm_group_label>
    <other_name>Gadoterate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY86-4875 (Gadobutrol; Gadovist®/ Gadavist®)</intervention_name>
    <description>Patients receive a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.</description>
    <arm_group_label>Arm 2_Confirmed CNS-lesion</arm_group_label>
    <other_name>Gadobutrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known or highly suspected central nervous system (CNS) pathology referred for
             contrast-enhanced MRI of the CNS.

          -  Glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m2 derived from a serum
             creatinine result within four weeks prior to the first study MRI.

          -  Women with negative urine pregnancy test within 1 hour prior to the administration of
             gadoterate (the first MRI).

        Exclusion Criteria:

          -  No enhancing lesion visible on the gadoterate-enhanced MRI scan.

          -  Pregnancy or breastfeeding.

          -  Severe cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU STRASBOURG - Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock - Medizinische Fakultät</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein (UKSH)</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein / AÖR</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Schiller-Uni. Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Provincia di Barletta-Andria-Trani</name>
      <address>
        <city>Andria</city>
        <state>Puglia</state>
        <zip>70031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Pisana</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS2 Marca Trevigiana</name>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <state>Ulsan Gwang''yeogsi</state>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 4HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gadolinium</keyword>
  <keyword>Contrast enhancement</keyword>
  <keyword>Central nervous system lesion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

